Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance by Lim, Jungeun et al.




organoids-on-chips: advancing preclinical drug 
screening with pathophysiological relevance
Jungeun Lim1,2, Hanna Ching1, Jeong‑Kee Yoon1, Noo Li Jeon2,3,4 and YongTae Kim1,5,6,7*  
Abstract 
Recent developments of organoids engineering and organ‑on‑a‑chip microfluidic technologies have enabled the 
recapitulation of the major functions and architectures of microscale human tissue, including tumor pathophysiology. 
Nevertheless, there remain challenges in recapitulating the complexity and heterogeneity of tumor microenviron‑
ment. The integration of these engineering technologies suggests a potential strategy to overcome the limitations 
in reconstituting the perfusable microvascular system of large‑scale tumors conserving their key functional features. 
Here, we review the recent progress of in vitro tumor‑on‑a‑chip microfluidic technologies, focusing on the reconstruc‑
tion of microvascularized organoid models to suggest a better platform for personalized cancer medicine.
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1 Introduction
Cancer pathophysiology is extremely complex since 
the  tumor microenvironment (TME) incorporates 
diverse factors, including extracellular matrix (ECM) 
and vascular constructs, with multiple stromal cell types 
[1]. Reproduction of the multiplex in vivo-like TME has 
been challenging due to the complexity and heterogene-
ity. The development of preclinical models pertinent to 
the pathophysiology of human cancers has contributed to 
clinical research for cancer therapeutics, and their roles 
are becoming more important [2]. Conventional preclini-
cal animal models have been widely applied to anti-can-
cer drug development [3, 4]. However, they are restricted 
by a limited throughput, ethical issues, costly and time-
consuming processes, and, more importantly, differences 
between animal and human physiology.
Recent advancement in 3D cell culture techniques to 
recapitulate human organ-specific microenvironment 
in vitro, which is known as organoids [5] or organs-on-
a-chip [6], has shown great potential to overcome the 
limitations of conventional animal models. Organ-on-a-
chip technologies and organoid models have emerged to 
better mimic the TME with human cells and to improve 
the efficiency with greater throughputs for more effective 
translational research for cancer treatment. TME-on-
a-chip techniques have advantages for coculturing vari-
ous cell types in TME under highly controlled dynamic 
microfluidic flow profiles to recapitulate essential physi-
ological phenomena in TME, while organoid technolo-
gies enable the development and reconstitution of 3D 
tumors retaining the inherent traits and the function of 
intact tumor tissues and the patient-derived TME and 
address intra- and inter-patient heterogeneity. Neverthe-
less, these technologies remain to be further developed to 
better reconstruct the notorious perplexity of TME. For 
example, it remains elusive whether tumor cells construct 
vessel-like channels themselves and connect to normal 
blood vessels or growth factors secreted by tumor cells 
induce blood vessels to grow into the tumor tissue [7]. 
Elucidation of the mechanism of tumor vasculogenesis 
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will contribute to modify the prognosis and therapy in 
cancer [8].
Recently, attempts to integrate organoids and organ-
on-a-chip technologies have shown the potential to 
synergize with each other. Notably, microvasculature-
on-a-chip techniques facilitate the establishment of 
vascular systems that have functional in  vivo-like solid 
tumors created by organoid engineering methods. In 
this Review, we highlight recent developments of micro-
vasculature-on-a-chip and tumor organoid formation 
and discuss how these techniques play an essential role 
in the research of vascular biology and oncology and 
in the development of cancer therapeutics. We review 
representative approaches using tumor organoids and 
microvasculature-on-a-chip to reconstruct a microvas-
cularized tumor system. Finally, we discuss the future 
perspective and challenges of this integrative technology 
named “microvascularized tumor organoids-on-a-chip” 
in reflecting intrinsic cancer traits on the preclinical 
modeling to facilitate cancer research and therapeutics 
development.
2  Tumor organoid
Over the past decades, advances in preclinical cancer 
models have contributed to the development of can-
cer research and therapeutics. Despite the remarkable 
progress in cancer treatment, many regimens have pre-
sented disappointing outcomes due to the  incomplete 
elimination of cancer cells. This fact mainly stems from 
the lack of understanding of tumor heterogeneity, which 
incorporates intra- and inter-tumor differences in gene 
expression, proliferation, metastatic feature, morphology, 
phenotype, and mutational profiles [9]. To address the 
challenge, it is essential to translate knowledge of cancer 
development from bench to bedside.
Standard oncology models like animal models and two-
dimensional in  vitro culture systems have widely been 
used for innovative discoveries of pathogenesis and ther-
apeutics in oncology in vivo [10–12]. They allow for pro-
found exploration; however, most of them lack complex 
human cancer traits. Similarly, 2D in vitro cancer mode-
ling does not truly reflect the pathological characteristics 
of the human TME. Patient-derived tumor xenografting 
(PDTX) models, which have been successful in replicat-
ing the significant portions of tumor multiplexity, com-
promise immune systems [13, 14].
Organoid technologies, which are 3D in  vitro con-
structs developed from self-organizing stem cells or pri-
mary tissue emulating in vivo tissue, have advanced the 
development of more physiological human models for 
translational research, as well as developmental stud-
ies. Beyond the potential of organoids to mimic normal 
human tissue microenvironment, this technology has 
been employed in cancer research to facilitate under-
standing of oncology and cancer therapeutics, termed 
tumor organoid [15, 16]. To date, tremendous efforts 
using human cell sources have been made to develop 
preclinical tumor organoid models of human cancers, 
including gastrointestinal, prostate, brain, kidney, and 
breast cancers.
2.1  Gastrointestinal cancer
Globally, about one-third of the entire incidence and 
mortality of cancer is associated with gastrointestinal 
cancers, which incorporates colorectal cancer, gastric 
cancer, liver cancer, and pancreatic cancer. So far, gastro-
intestinal tumor organoids have been cultured to reca-
pitulate  the functions and architectures of these cancer 
types.
2.1.1  Colorectal cancer
Worldwide, colorectal cancer, which is a tumor that 
develops from the colon or rectum, is one of the most 
common cancers [17]. Colorectal cancer modeling via 
tumor organoid has been developed using culture con-
dition to enable the long-term culture of villus-like epi-
thelial architectures [18] and CRISPR-Cas9-editing 
techniques [19–21] from human patient-derived tis-
sue acquired by surgical resection or endoscopy biopsy, 
establishing an organoid library [22]; other colorectal 
tumor organoids derived from surgical resection were 
applied to high-throughput drug screening [23–25]. 
Furthermore, colorectal tumor organoids extracted by 
patient tissue biopsy of metastatic lesion were used to 
compare the reactions to anti-cancer agents with the 
responses to the patients in clinical trials [26] as well as 
stored in the collection [27, 28].
2.1.2  Gastric cancer
Gastric cancer remains the third most common cause 
of cancer-related deaths of all malignancies worldwide 
[29]. To emulate the pathophysiology of gastric cancer, 
a standard protocol for gastric tumor organoids forma-
tion was established to represent the traits of each of its 
four subtypes [30] and recapitulate most of the critical 
hallmarks of bacterial infection using surgically resected 
tissue of patients [31, 32]; CRISPR-Cas9-editing method 
was used to modify gastric cancer organoids to model 
each of the four subtypes of gastric cancer [33]. Using 
patient tissue specimen of the metastatic insult, a library 
of gastric tumor organoids to study chemosensitivity was 
demonstrated [26].
2.1.3  Liver cancer
Internationally, primary liver cancer is the fourth lead-
ing cause of cancer mortality [29]. The histological and 
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genetic features and metastatic characteristics of hepa-
tocellular carcinoma were replicated using surgically 
resected primary liver cancer patient tissue [34]. Besides, 
long-term hepatocellular carcinoma organoid cultures 
from tumor needle biopsies of liver cancer patients were 
established [35]. The organoids preserve the genetic 
heterogeneity, the tumor marker expression, and the 
morphology of the originating tumors presenting the 
application of the tumor organoids as a tool for testing 
cancer treatments.
2.1.4  Pancreatic cancer
The incidence of pancreas cancers continues to rise [17], 
one of the major causes of cancer death [36]. To estab-
lish pancreatic cancer modeling, surgically resected 
pancreatic cancer patient tissue derived from resected 
tumors or biopsies has been contributed to constructing 
pancreatic tumor organoids with retaining morphologi-
cal heterogeneity and histological structure and building 
tumor organoids biobanks [37, 38]; therapeutic profiling 
was performed through the tumor organoids as a tool 
[39, 40]. Moreover, CRISPR-Cas9 technology enabled the 
reconstitution of progression from pancreatic intraepi-
thelial neoplasia to adenocarcinoma using pancreatic 
cancer patient specimens [41, 42].
2.2  Prostate cancer
Prostate cancer incidence and deaths have increased 
in the recent past few years [43, 44]. As prostate cancer 
modeling tools, the prostate tumor organoids were gen-
erated using metastatic human prostate cancer lesions 
and circulating tumor cells [45, 46]. The studies for pros-
tate tumor organoids demonstrated that the organoids 
created from human patient tumor specimens with 
detailed characteristics were amenable to drug testing 
[45] and study of prostate cancer initiation [47].
2.3  Brain cancer
Among adolescents and children, brain cancers, includ-
ing glioma, glioblastoma, and medulloblastoma, are the 
most common cancer and one of the leading causes of 
cancer-specific death [48]. Brain tumor organoid mod-
els derived from human embryonic stem cells were 
built via tumorigenic mutations using transposon and 
CRISPR-Cas9 technologies to study the human brain 
tumor developmental process incorporating initiation 
and progression [49]. Resected tissues of glioblastoma 
patients were utilized to build glioblastoma organoids 
to reconstitute hypoxic gradients, and stem cell hetero-
geneity was constructed [50]. Interestingly, glioblastoma 
modeling was developed using human embryonic stem 
cells-derived cerebral organoids with invasion of patient-
derived glioma stem cells, which replicated the biological 
behaviors, genetic features, and phenotypes of human 
glioblastoma [51].
2.4  Kidney cancer
In the United States, at least 300,000 kidney cancer sur-
vivors have or will develop chronic kidney disease [52]. 
Renal carcinoma organoids recapitulating the pheno-
typic traits were generated using human tissue speci-
mens [53, 54]. Also, the pediatric kidney cancer tissues 
extracted through nephrectomy or biopsy were utilized 
to derive kidney tumor organoids from retaining phe-
notypic and histological characteristics of the parental 
tumor tissue [55].
2.5  Breast cancer
Among females, breast cancer is the leading cancer and 
the main cause of cancer-related death [29]. Human 
breast tumor biopsies were applied to establish breast 
tumor organoids to reconstruct the basement mem-
brane [56] and identify drug response [57]. In addition, 
a living biobank of breast tumor organoids to maintain 
genetic and histological traits of parental tumors was 
built, which enabled high-throughput drug screening 
[58]. As one of the  breast cancer types, the papillary 
carcinoma organoids to mimic the histological fea-
tures and the biomarker expression were created using 
patient tumor tissues [59].
2.6  Others
Various types of tumor organoids have been engi-
neered to reconstruct specific microenvironments 
in tumors, such as the immune system. For instance, 
air-liquid interface tumor organoids derived from sur-
gically resected patient tumor tissue emulated the 
programmed cell death protein 1/ programmed death-
ligand 1 (PD-1/PD-L1)-dependent immune check-
point, which is a key regulatory physiological immune 
checkpoint [60]. Furthermore, the platform for the 
implementation of personalized high-throughput drug 
screening with whole-exome sequencing analysis was 
constructed via patient-derived multiple types of can-
cer organoids [61].
3  Microvasculature‑on‑a‑chip
Microvascular networks are composed of terminal 
arterioles, capillaries, and postcapillary venules, where 
the blood flow and drainage occur. The microvascu-
lar system is essential in human physiology as a cir-
culatory network to deliver nutrients and oxygen and 
eliminate the waste products and  CO2 by constructing 
inter-organ connections [68]. Since this circulatory sys-
tem plays an integral part in human metabolism and is 
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immensely associated with pathophysiology, it is cru-
cial to reconstitute the structure in preclinical mod-
els. Reconstructing the microvascular architecture and 
function, such as endothelial barriers and vascular per-
fusability, has been challenging for the development of 
conventional in vitro preclinical models.
To overcome the limitations, organ-on-a-chip sys-
tems provide for a controllable 3D tissue culture mod-
ule, allowing to emulate the microvascular network. 
The 3D microfluidic in vitro model has enabled the cul-
ture of microvasculature in a dynamic microenviron-
ment, termed microvasculature-on-a-chip. Recently, the 
dynamic stimulation, such as the blood flow-mimicking 
shear stress, advanced the physiological relevance in 
terms of its function, morphology, and junction expres-
sion. Here we reviewed microfluidic in  vitro models to 
reconstruct the microvasculature using human endothe-
lial cells (ECs) by categorizing them based on engineering 
aspects: self-assembled microvascular network, EC mon-
olayer, and tubular endothelial barrier.
3.1  Self‑assembled microvascular network
A network of blood vessels establishes the circulatory sys-
tem, regulating the systemic process by transporting vital 
substances. Through the circulatory path, drugs are dis-
tributed throughout the body. Of particular interest is the 
study to replicate the essential microvascular organiza-
tion related to multiple pathologies and drug treatment. 
The adjusted microenvironments by engineering cellular 
elements, extracellular matrix, mechanical stress, and 
other factors enable the reconstitution of the connected 
microvascular network with a lumenized structure via 
the self-organizing ability of ECs. This type of in  vitro 
model allows for the construction of blood vessels hav-
ing diameters in tens of micrometers. Also, this platform 
emulates fundamental mechanisms in microvasculature 
formation, known as angiogenesis and vasculogenesis, in 
the orchestrated microenvironment.
The gradient of soluble angiogenic factors generated by 
the microfluidic system induced sprouting angiogenesis 
via the self-organizing process of seeded ECs [69]. Using 
a strategy to promote vasculogenesis and angiogenesis 
via secreted agents from cellular components, 3D func-
tional microvascular networks can be built from ECs in 
microfluidic devices. For instance, a perfusable microvas-
culature was constructed through both vasculogenesis 
and angiogenesis of ECs embedded in fibrin gels sup-
ported by factors released from fibroblasts in the micro-
fluidic device compartmentalizing each cellular portion 
using gel-trapping micropost structure [62] (Fig. 1a). The 
microfluidic platform with microposts also enabled to 
measurement of the permeability of lumenized microves-
sels generated by angiogenesis [70]. With a similar gel-
trapping approach, the vasculogenesis-like process was 
supported by bone marrow-derived human mesen-
chymal stem cells, which release proangiogenic factors 
[71]. Also, the microvascular construct was generated 
by injecting fibrin gel loaded with normal human fibro-
blasts and endothelial colony-forming cell-derived ECs in 
each environmental condition: interstitial flow or hypoxic 
conditions [72]. The lumen structure constructed by 
this module was perfused by connecting to microfluidic 
channels to present an engineered anastomosis system 
[73, 74]. This platform exhibited flexibility to culture 
microvessels in high-throughput methods [75] integrat-
ing with multiple components, including tumor and car-
diac muscle tissues [5].
The self-morphogenic microvascular engineering 
method has been applied to the studies for the effects of 
various stimulations and constituents on the microvascu-
lature. The angiogenic sprouting response to mechanical 
cues, including shear stress [76], interstitial flow [77, 78], 
magnetic stimulation [79], and compression [80], was 
investigated using the self-organized microvasculature 
(See figure on next page.)
Fig. 1 Microvasculature‑on‑a‑chip technology. a Microfluidic platform to reconstruct a self‑organized microvascular network. Configurations and 
confocal microscopy images presenting the microvasculature constructed by (i) vasculogenesis (scale bar: 100 μm) and (ii) angiogenesis (scale bar: 
20 μm) at day 4. [62]. b Self‑assembled BBB microvascular network. Schematic diagram of BBB‑on‑a‑chip consisting of endothelial cells, astrocytes 
(ACs), and neurons (top). Confocal microscopy images of astrocytes (GFAP, white), neurons (Synaptophysin, green), and microvasculature (CD31, 
red) (bottom‑left). Immunostaining of CD31 (red) and tight junctions, ZO‑1 (green) of the vascular network—astrocyte interface (bottom‑right). 
[63]. c Microfluidic device to culture endothelial barriers. Configurations of blood‑lymphatic endothelial cells layer culture (top). Immunostaining 
of an endothelial‑specific protein, claudin‑5, and an endothelial‑specific adhesion molecule, VE‑cadherin (bottom). Scale bar, 100 μm. [64]. d BBB 
structure emulated by the microfluidic culture of endothelial cells monolayer. Schematic representation of the microfluidic BBB model (top). 
(i) Confocal image of the bottom of the chip with endothelium (ZO‑1, red) and network of astrocytes (GFAP, white). Scale bar, 50 µm. (ii) Tight 
endothelial monolayer (ZO‑1, red; DAPI, blue), pericytes cultured under the porous membrane (α‑SMA, green; DAPI, blue), and astrocytes labeled 
with GFAP (GFAP, white) and S100β (S100β, magenta). Scale bar, 50 μm [65]. e Tubular endothelial barrier‑on‑a‑chip. Schematic representation of 
the microfluidic system(top). Confocal microscopy images of the overall endothelialized ductal structure and the magnified section of network 
corner (red, CD31; blue, nuclei) (bottom). Scale bar, 100 μm [66]. f Ductal structure of BBB reproduced by microfluidic technology. Cross‑section 
view of the center of the chip for a three‑lane coculture system of endothelial cells, pericytes, and astrocytes (top). (i) Z‑stack confocal image of 3D 
reconstructed BBB (Calcein‑AM, green and magenta; PECAM‑1, red; nuclei, blue). (ii) Images of FITC‑dextran (20 kDa) perfused in the microchannels 
[67]
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models. In the microvascular environment, the angio-
genic sprouting was induced when a shear stress thresh-
old was surpassed [76]. The interstitial flow promoted 
angiogenic sprouting when the flow direction was oppo-
site from sprouting, while the flow given in the same 
direction inhibited the sprouting in the microfluidic plat-
form [77]. Also, low interstitial flow in the microfluidic 
system eliminated the spatial gradients of morphogen 
and maneuvered angiogenic growth [78]. Magnetic bead 
movement enhanced microvessels growth [79], while 
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compressive force increased reactive oxygen species and 
vascular leakiness [80]. The response of the microvascu-
lar plexus subjected to other types of stimulation caused 
by nanoparticles [81–83], anti-neovasculogenic agents 
[84], fine particulate matter [85], and airborne nanoscale 
particles [86] was examined using the microfluidic mod-
els. Furthermore, the cellular component and ECM are 
also important cues to modulate the microvascular envi-
ronment. For example, the mature and functional vascu-
lar network was established by the self-morphogenesis 
process of induced pluripotent stem cell (iPSC)-derived 
ECs in synthetic hydrogels [87] and the fibrin gel [88]. 
Also, this platform allowed to investigate the interaction 
between perivascular cells and microvascular constructs. 
Specifically, the microfluidic platforms demonstrated the 
contribution of pericytes to inhibiting the enlargement of 
microvessels and constructing a dense network [89] and 
the connecting mechanism between the vessel-like struc-
tures in the spheroid of human lung fibroblasts and the 
sprouts of microvessels [90].
Beyond engineering each component and stimula-
tion, the self-organized microvasculature-on-a-chip 
techniques were applied to recapitulating microvascu-
lar systems in multiple organs. For instance, angiogen-
esis in bone was reconstituted by culturing angiogenic 
sprouts in a mineralized ECM consisting of hydroxyapa-
tite [91] and inducing bone marrow angiogenic process 
by leukemia cells [92]. Besides, the subcutaneous blood 
vessels replicated by coculturing human ECs with der-
mal fibroblasts and keratinocytes exhibited enhanced 
angiogenesis during exposure to skin-irritation agents, 
which was proposed as an in vitro skin-irritation model 
[93]. The function of microvasculature in the brain, such 
as the  brain-blood barrier (BBB) and blood-retinal bar-
rier (BRB), was emulated using this type of microfluidic 
model [63, 94–98]. BBB-on-a-chip was developed by 
integrating various types of ECs with cellular constituents 
in the BBB microenvironment, such as astrocytes, peri-
cytes, and neurons. The microfluidic coculture system 
consisting of astrocytes, neurons, and human umbilical 
vein endothelial cells (HUVECs) enabled to the  repro-
duction of  low permeability of the vasculature, which is 
one of the critical physiological features of BBB by adjust-
ing media conditions [63] (Fig.  1b). Furthermore, BBB 
structures exhibiting physiological characteristics of BBB, 
including enhanced junction proteins, were engineered 
by combining astrocytes and pericytes with ECs such 
as human brain microvascular ECs [94] and iPSC-ECs 
[95]. Using this approach using iPSC-ECs, the transport 
of polymer nanoparticles across BBB was evaluated [96]. 
Moreover, the outer BRB mimicked in microfluidic chips 
shows the anatomical structure of outer BRB with higher 
trans-epithelial electronic resistance value than the value 
of the epithelial monolayer [97] and the pathophysiologi-
cal process of age-related macular degeneration [98].
For high-throughput culturing and drug screening sys-
tems of self-assembled microvascular network in  vitro 
models, facilitating 3D gel patterning to encapsulate 
endothelial and other cells is one of the most required 
manipulations. To allow for simple gel trapping, open 
microfluidics was employed to injection-molded micro-
fluidic chips, which enables to mimic the BBB construct 
[99], tumor microvasculatures [100], and the ocular neo-
vascularization [101].
3.2  Endothelial cell monolayer
One of the structural characteristics of the blood vessel 
is that ECs are aligned in a single layer in contact with 
circulating blood. A monolayer of ECs, known as the 
endothelium, is one of the essential architectures in the 
human body system. This structure regulates multiple 
physiological processes such as immune mechanisms, 
the transport of blood cells, and the control of vascular 
tone [102]. The input from the microenvironment such 
as biomechanical forces, including shear stress and cyclic 
strain, determines the endothelial phenotype [103]. To 
reflect the features of the endothelium on in vitro mod-
els, the microfluidic system which provides the dynamic 
environment has been employed to reconstruct the EC 
monolayer. Controlling the microfluidic condition in 
each EC culture system enabled a long-term culture of 
the ECs layer, which maintains cellular viability and pro-
motes the expression of the EC marker proteins as well as 
adhesion molecules elevated by the effects of the inflam-
matory cytokines [104].
Thanks to the strategy, a wide range of barrier func-
tions of numerous organs such as the  lung [105–108], 
lymphatic vascular system [64], placenta [109–113], skin 
[114], brain [65, 115, 116], and gut [117] has been emu-
lated in  vitro. A lung model is composed of an alveolar 
epithelium and an endothelium on the opposite sides of 
a porous membrane and is subjected to a respiration-
mimetic dynamic motion controlled by a vacuum system 
[105]. This microfluidic device facilitated reproducing the 
effects of physiological breathing on nanoparticles uptake 
[105] and drug-toxicity-induced pulmonary edema pro-
gression, incorporating the development of vascular leak-
age [106]. A lung-on-a-chip array was also developed by 
exposing the endothelial and epithelial layer on both sides 
of the porous membrane to cyclic strain using an elec-
tro-pneumatic set-up [107]. Using the alveolar-capillary 
interface barrier built by patterning human pulmonary 
alveolar epithelial cells and ECs on the opposite sides of 
the Matrigel membrane in the microfluidic chip, the pul-
monary response to air pollutant PM2.5 were assessed 
[108]. A microcirculation system consisting of blood and 
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lymphatic vessels was reproduced by coculturing both 
blood and lymphatic ECs on the porous membrane under 
flow conditions, which promote endothelial cell-cell junc-
tions [64] (Fig.  1c). Moreover, a multi-layered structure 
of human trophoblasts and ECs on a porous membrane 
subjected to dynamic flow mimics the architecture of the 
human placental barrier and physiological transport of 
glucose [109, 110] and drug [111] across the maternal-
fetal interface. The placental inflammatory responses 
with bacterial infection were investigated via the recon-
structed placental barrier using a similar approach [112]. 
Also, the placental transport of nanoparticles was exam-
ined using a placental barrier-on-a-chip fabricated by 
coculturing trophoblasts and ECs on the opposite sides 
of ECM [113]. The interlayer interaction provided by the 
microfluidic system allowed for the reconstitution of the 
complex skin structure consisting of epidermal, dermal, 
and endothelial layers, where inflammation and edema 
were induced in this model [114]. The neurovascular 
construct established by coculturing neurons, astro-
cytes, and ECs layers vertically patterned on gel walls 
under dynamic flow exhibited size-selective permeability 
[115]. Particularly, the function and morphology of BBB, 
including low permeability of the barrier and the expres-
sion of efflux pumps and transporters, were recapitulated 
by culturing ECs layers interfaced with astrocytes and 
pericytes under shear flow [65, 116]. The BBB structure 
engineered by brain-like microvascular ECs derived by 
iPSC technology demonstrated the improved barrier 
function under hypoxic conditions [116]. Besides, the 
barrier architecture consisting of human microvascular 
ECs allows for neuroinflammation modeling by establish-
ing an astrocytic network with reduced reactive gliosis 
markers while enables nanoparticles transport testing 
[65] (Fig.  1d). The human gut-vessel microenvironment 
with a peristaltic motion was reconstituted by culturing 
intestinal epithelial cells-ECs under a pneumatic pump-
ing system, which emulates the intestinal barrier damage 
and inflammatory reactions caused by E. coli [117].
Numerous microengineering technologies serve as 
a tool to construct microfluidic platforms to replicate 
endothelial barriers [118–120] and evaluate the barrier 
function [121, 122]. For instance, a semipermeable and 
optically transparent membrane created by a hydrogel 
engineering technology enabled to promote endothelial 
cellular adhesion and growth under microfluidic flow 
while compartmentalizing the microenvironments [118]. 
A pumpless microfluidic device designed for directional 
perfusion provided continuous fluid flow driven by grav-
ity to organize extensive endothelial barriers [119]. Also, 
a hydrophobic-patterning technique facilitated gel load-
ing in the microfluidic platform without microposts to 
guide the route, where a confluent EC monolayer was 
constituted on the patterned gel wall [120]. To assess the 
mechanical and chemical effects, including shear stress 
on the endothelial barrier culture, the microfluidic plat-
forms were designed to measure the permeability of the 
ECs layer using tracer molecules with varying sizes [121] 
and transendothelial electrical resistance [122]. Further-
more, the influence of external substances such as che-
moattractant [123] and gold nanoparticles [124] on the 
microenvironment of endothelium under fluid flow was 
investigated using engineered microfluidic platforms.
3.3  Tubular endothelial barrier
The microcirculation operated by distributing blood to 
tissues through ductal structures of vessels plays a vital 
role in human pathophysiology. Notably, the mechanical 
and rheological properties determined by multiple vari-
ables such as blood flow, blood cell behaviors, and inter-
action between blood cells and the vascular wall during 
ducal flow considerably affect the microcirculatory sys-
tem [125]. Thus, the tubular structure of microvascu-
lature is crucial to understand the hemodynamics [126] 
and the dysfunction of the system [127], which is impor-
tant for therapeutic developments. In  vitro microfluidic 
models to reconstruct the tubular lumen structures of 
endothelial barriers have been established to implement 
the strategies to explore unaddressed questions related to 
the pathophysiology [128].
Multiple types of engineering techniques were 
employed to fabricate fit-for-purpose microfluidic plat-
forms to build the ductal structure of the ECs layer. To 
reproduce the vascular disorders induced by pathologi-
cal oxygen stress and shear flow, the ECs layers on the 
fibronectin-coated walls of tubular microchannel were 
cultured in hypoxic conditions under fluid flow [129]. 
Through a hydrogel casting process using a 3D print-
ing technique, a confluent ductal layer of ECs was con-
structed on the microchannel walls consisting of gelatin 
methacrylate (GelMA) [130]. A microfluidic model to 
recapitulate angiogenesis, tubulogenesis, and anasto-
mosis developed from tubular microvascular structure 
also utilized a photo-crosslinkable material, GelMA 
[131]. On the other hand, ductal microvasculatures-on-
a-chip manufactured using photo-degradable hydrogels 
allowed for geometrical control [132]. A molding pro-
cess using the microwire also enabled the controllable 
design of tubular structure to emulate vascular compli-
ance and topography [133]. Moreover, the microfluidic 
tubular vasculature model, which can be applied to the 
anastomosis, was developed by integrating a synthetic 
biodegradable polymer with 3D stamping technology 
[134]. The in vivo-like ducts were also built by aligning 
smooth muscle cells and ECs on microwrinkled circular 
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microchannels constructed via the soft-lithographic 
molding process [135].
To examine the behavior of blood cells and blood flow 
during the microcirculation, a certain type of blood 
cells such as red blood cells (RBCs) and white blood 
cells were inserted in the tubular endothelial barriers-
on-a-chip. For example, RBCs were introduced to the 
perfusable capillary tube, which was created by fus-
ing migrating ECs from opposite ends along patterned 
fibrin gels in the microchannels [136]. Besides, the 
effects of endothelium on the behavior of RBCs around 
the endothelial wall under hydrodynamic resistance 
were examined using ductal endothelial microchannels 
built by the soft-lithography technique [137]. RBCs are 
also perfused in ECs layer-covered microchannel under 
mechanical stress to mimic damage on the pulmonary 
microvasculature that occurred during RBCs transfu-
sion and breathing [138]. Particularly, an agarose-gel-
atin interpenetrating polymer network hydrogel was 
utilized to fabricate a tubular endothelialized fluidic 
system, in which sickle RBCs were loaded in the chan-
nels to investigate the endothelial barrier dysfunction 
in sickle cell disease [139]. Moreover, neutrophil, one 
of the types of white blood cells, was introduced in the 
endothelial tubes constructed in microfluidic channels 
with varying bifurcation angles [140] and mold-casted 
microchannels [141, 142] to examine the interaction 
between endothelium and neutrophils. Beyond inject-
ing each type of blood cells, whole human  blood was 
infused into the tubular structure of endothelial bar-
riers. Whole blood was inserted through the cylindri-
cal ECs barriers on microchannels fabricated using a 
biocompatible sacrificial molding [143]. The collagen 
scaffolds to form tube-shaped microvessels were manu-
factured via a molding process and utilized to examine 
the prothrombotic state under the inflammatory stim-
ulation by injecting human blood into the ducts [66] 
(Fig.  1e). Likewise, more adhered monocytes on the 
inner endothelial surface of the lumen were investigated 
in the presence of an inflammatory cytokine than in the 
absence of the stimulation using the endothelial ducts 
in microfluidic channels manufactured by 3D stamp-
ing technology [144]. Also, platelet aggregation was 
observed when whole blood was perfused in 3D printed 
microfluidic chips with a stenotic geometry [145] and 
constricted microchannels generated by the  collagen-
patterning method emulating stenosis in atherosclero-
sis [146]. Interestingly, a bleeding model was developed 
by coupling the microfluidic chip fabricated by soft 
lithography with a pneumatic valve to induce vascular 
injury of endothelial barriers, which allowed for the 
investigation of the effect of antiplatelet agents on clot 
retraction and hemostatic plug formation [147].
Recent studies have also presented the application of 
the tubular ECs layer-on-a-chip technology to replicat-
ing the microvascular system in other organs such as skin 
[148] and BBB [67]. For instance, a skin-equivalent model 
was established by constructing the ductal microchannel 
in the collagen scaffold containing dermal fibroblasts and 
epidermal keratinocytes, coating the inner surface of the 
channel with ECs and perfusing media using a pumping 
system [148]. Furthermore, tubular BBB structure with 
adherens and tight junctions was reproduced by cocul-
turing ECs, astrocytes, and pericytes in the commercially 
available microfluidic platform, which was utilized to test 
antibody transcytosis [67] (Fig. 1f ).
4  Microfluidic approach to reconstitute 
vascularized solid tumors
4.1  On‑chip tumor spheroids formation using 
microfluidics
A tumor spheroid is a 3D cell cluster with a spherical 
structure derived from a variety of tumor cell lines or 
even with other tumor-related cells [151]. Tumor sphe-
roid formation became of interest because they better 
recapitulate the in vivo TME, and resultantly, provides a 
more accurate platform for biological studies and thera-
peutic testing. Tumor cells are formed into spheroids to 
better replicate the in  vivo TME. This allows for more 
accurate biological studies and therapeutic testing. Con-
ventional tumor spheroid forming techniques include 
hanging drop [152], liquid overlay [153], spinner flask 
[154], and NASA’s rotating wall vessel (RWV) [155]. In 
addition to formation, these techniques also accommo-
date drug testing and performance analysis. Since tumor 
spheroids, Nevertheless, the conventional methods have 
their drawbacks as the dynamic culturing systems (spin-
ner flask and RWV) require large volumes of media, 
and the static culturing systems (hanging drop and liq-
uid overlay) are laborious and require frequent media 
exchanges [151]. To overcome these challenges, micro-
fluidics has become a popular solution that commonly 
includes hydrodynamics [149], hydraulic resistance [156], 
droplet [157], and microwells [150] for tumor spheroid 
culturing (Fig.  2). Microfluidics advanced spheroid cul-
turing techniques by providing higher controllability over 
spheroid size and growth parameters, continuous perfu-
sion, and faster formation [158].
4.2  Applying 3D tumor spheroids 
to microvasculature‑on‑a‑chip devices
Organs-on-a-chip approaches have extended their poten-
tials to reconstructing TME [159–161]. Furthermore, 
to replicate the crucial features of the microvascular-
ized tumor complex, such as tumor angiogenesis and 
metastasis [162–165], the microfluidic tumor-on-a-chip 
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incorporating a microvascular compartment has been 
developed [166]. The self-assembly microvascular engi-
neering approach has facilitated to reconstruct tumor 
angiogenesis [62, 167] and tumor vasculature for analysis 
of patient-derived tumor cellular behaviors on the net-
work [168] and anti-cancer drug testing [100, 169–171]. 
This self-organization method has also been applied 
to emulate metastatic cascade such as extravasation of 
tumor cells [172–175], including when the TME is in 
the bone matrix [176] or hypoxic condition [177]. As 
another technique to reconstitute microvasculature, the 
endothelial monolayer organized with tumor cells in the 
microfluidic platform has provided a reliable module to 
recapitulate tumor behaviors on the endothelial barrier 
[178], including metastatic response [179, 180] such as 
transendothelial invasion [181, 182], intravasation [183–
186], and extravasation [187]. Moreover, integrating 
tubular endothelial barriers-on-a-chip with cancer cells 
has enabled to  the investigation of transvascular migra-
tion of tumor cells [188] and assess anti-drug efficacy 
[189] and nanoparticle extravasation [190] in the micro-
fluidic model. As described above, considerable progress 
in translational research to understand vascular oncology 
has been achieved by combining single tumor cells with 
microvasculature-on-a-chip techniques.
Nevertheless, the aforementioned models present 
constraints in emulating the  pathophysiology of solid 
tumor tissue with microvascular plexus. To understand 
the microenvironment of solid tumor microvascula-
ture is crucial because solid tumor with the abnormal 
microvasculature leads to regions of hypoxia and acid-
ity [191, 192]. These unique physiological characteristics 
influence drug resistance to chemotherapy and anti-
angiogenic factors, which is critical in cancer treatment 
[193–196]. 3D tumor tissues assembled in a microsphere, 
known as tumor spheroids, have been orchestrated with 
microvasculature-on-a-chip to address the challenges. 
To date, the microfluidic platforms to culture engineered 
tumor spheroids with the microvascular system have 
been developed (Table. 1) to reconstitute microvascu-
larized solid tumors of numerous organ types, including 
lung, colon, brain, ovary, stomach, and breast. Unlike 
the microfluidic models depicted in Table. 1, where 3D 
tumor spheroids cultured in separate platforms were 
incorporated in microvasculature-on-a-chip, the tech-
nologies to assemble solid tumor tissue and construct 
a microvascular structure in the microfluidic platform 
at once have been developed [197–200]. The innovative 
combination of solid tumor tissue formation techniques 
and microvasculature-on-a-chip technologies has con-
tributed to translational cancer research.
5  On‑chip approaches for microvascularized 
tumor organoids
As previously described, exploring the physiological 
interaction of microvessels and solid tumor tissue is con-
siderably significant in understanding oncology and can-
cer therapeutics. Though the integration of 3D tumor 
spheroids with the microvascular system in  vitro con-
tributed to this understanding, the current unmet goals 
of the models are to recapitulate the highly complex 
TME and heterogeneity of each patient tumor. Beyond 
the in vitro system to encompass the cellular aggregates 
and the microvessels, multiplexed microfluidic systems 
have been developed by combining organoids technolo-
gies with microvasculatures-on-a-chip systems. The 
microvascularized 3D tissues retain their functions and 
features representing the original in  vivo tissues and 
increase the complexity of the microenvironments incor-
porating the microvascular system.
The microfluidic platform to engineer microvas-
cularized organoids was demonstrated by providing 
the controllable fluid perfusion on the collagen cylin-
ders consisting of liver cancer cells and surrounded by 
HUVECs [212] (Fig.  3a). Likewise, vascularized kidney 
organoids were constituted using pretubular aggregates 
Fig. 2 Microfluidic systems for tumor spheroid culturing. a A microfluidic device that utilizes hydrodynamics to guide cancer cells into U‑shaped 
traps and form tumor spheroids. This method highlights the controllability over the number of cells in each spheroid, the ability to sustain 
long‑term culturing, and on‑chip drug testing, which are features not present in conventional methods [149]. b A tumor spheroid culturing device 
that combines microfluidic principles and cell suspension techniques. The cell suspension injected through the PDMS channel was gathered in the 
pyramid‑like holes to be aggregated. The device supports spheroid formation and long‑term culture [150]
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differentiated from human pluripotent stem cell-derived 
metanephric mesenchyme cells under controllable flow 
on milifluidic chips [216]. The dynamic microenviron-
ment in the platform contributed to enhanced endothe-
lial maturity and vascularization with perfusable lumens 
as well as more mature podocyte and tubular portions. 
For a vascularized liver organoids modeling, induced 
hepatic cells were cocultured with HUVECs in a decel-
lularized liver extracellular matrix loaded in a microflu-
idic platform with a rocker system [213] (Fig. 3b). Under 
the gravity-driven flow in the system, the liver orga-
noids presented induced vascularization by HUVECs 
and extended albumin expression. In addition to the 
studies integrating normal organoids with vascular net-
works, patient-derived tumor organoids were loaded in 
the self-organized microvasculature-on-a-chip, although 
the tumor organoids lack the characteristics of 3D solid 
tumor tissue [214] (Fig. 3c). The microvascular network 
cultured with patient-derived tumor organoids presented 
highly angiogenic features. Using a customizable micro-
fluidic platform, ECM components and the culture media 
composition were adjusted to coculture patient-derived 
colon organoids and a self-assembled microvasculature 
under intravascular perfusion [215]. This device was 
Fig. 3 Modeling for vascularized organoids‑on‑a‑chip. a The approach for collagen‑HepG2 modules to build vascularized organoids. The HepG2 
cells collagen cylinders covered with human umbilical vein endothelial cells (HUVECs) were cultured in the flow circuit enabling perfusion with 
medium or blood to deliver nutrients to the assembly. Confocal microscopy image of (i) vascular endothelial (VE)‑cadherin staining of HUVEC 
layer on the construct and (ii) prelabeled viable HepG2 cells [212]. b 3D vascularized hepatic organoids in a rocker‑actuated microfluidic system. 
Confocal images for CD31 (green) and albumin (ALB; red) of the liver organoids consisting of induced hepatic cells, HUVECs, and a decellularized 
liver extracellular matrix cultured under each condition demonstrate increased albumin expression and vascular network of the liver organoids 
when cultured with media flow: under static conditions (iHE‑S) and dynamic conditions induced by the microfluidic system (iHE‑F). Scale bars, 
500 μm (white), 50 μm (yellow) [213]. c A microfluidic device to coculture patient‑derived tumor organoids (PDTO) and a perfusable microvascular 
networks. Fluorescently tagged PDTOs (red; scale bar, 50 μm) cultured in the microfluidic chip grow in the pre‑vascularized system. The vascular 
network (green; scale bar, 100 μm) cocultured with PDTOs show highly angiogenic features [214]. d A microfluidic platform to engineer vascularized 
colon organoids. Confocal microscopy images of vascularized colon organoids for F‐actin (red), DAPI (blue), and GFP‐endothelial cells (green). [215]
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applied to the reconstitution of a colorectal inflammation 
with an innate immune function in the circulatory system 
was reconstituted in this device by applying monocytes 
and inflammatory cytokines to the microenvironment.
Upon embedment of functional organoids into micro-
vasculature-on-a-chip, multiplexed microvascularized 
“on-a-chip” models will be constructed by addressing the 
key hurdles. Representation of an in vivo-like microenvi-
ronment using the platforms allows for the development 
of therapeutics and biological studies. Likewise, emulat-
ing vascularized TME by incorporating tumor organoids 
into microvascular beds contributes to the advance in 
cancer treatment and research (Fig. 4).
6  Conclusions
The current organoid and organ-on-a-chip technolo-
gies have contributed to the recapitulation of human 
cancer pathophysiology. Although the tumor organoids 
and TME-on-a-chip techniques have provided promis-
ing tools for preclinical studies, multiple challenges such 
as mimicking the systemic delivery of anti-cancer drugs 
remain for advanced applications. One of the recent 
strategies is the microvascularization of tumor orga-
noids, which allows to mimic a physiologically relevant 
molecular transport system to provide nutrients to tumor 
organoids or to deliver anti-cancer drugs, highlighting 
the importance of this technology integration.
However, several challenges still have to be overcome in 
microvascularized tumor organoids in terms of materials 
and design. First, media formulations and ECM compo-
nents should be adjusted to induce microvascularization 
in tumor organoids during their organogenesis. Moreo-
ver, the development of alternative materials is required 
because polydimethylsiloxane, which is the most widely 
used material in the manufacturing of microfluidic plat-
forms, severely adsorbs biomolecules to decrease the 
accuracy of drug testing. A new module for a highly 
controllable dynamic environment needs to be estab-
lished to precisely control the organogenesis and micro-
vascular growth. Following this, organ-on-a-chips with 
microfluidic systems could provide more precise control 
over the organogenesis than conventional methods. This 
microsystem can also directly lead to drug testing with-
out further transfer or disturbance of the spheroids with 
minimal waste by easily integrating biosensors.
Here, we highlighted tumor organoids cultures, micro-
vasculature engineering, and microfluidic techniques, 
which may serve as versatile tools to reproduce TME with 
pathophysiological relevance. The established perfus-
able tumor culture system incorporating microvascular 
networks with high functional resemblance to the patient 
Fig. 4 Microvascularized tumor organoids‑on‑a‑chips principles
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tumor may allow for continuous growth and maturation of 
tumor tissue via microcirculation. This synergistic strategy 
to reconstruct microvascularized tumors may play a criti-
cal role in the development of personalized cancer therapy. 
Consequently, we expect that further studies to integrate 
the microvascularized tumor model with a complex mech-
anism, such as an immune system, enable the close repro-
duction of cancer pathophysiology.
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